Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Tuesday. Allison Transmission Holdings, Inc. (NYSE: ALSN) Started as Neutral at Credit Suisse;…
Earnings season is in full swing and we have many key reports due in the coming week. 24/7 Wall St. has provided some detailed previews for the key earnings reports we expect…
Gasoline dipped below $3.90, based on the AAA assessment of the average price for a gallon of regular nationwide. The price yesterday was $3.891, down from $3.899 the day before and $3.907 a…
Illumina (NASDAQ: ILMN) shareholders may be in for a rude surprise. Suitor Roche could be close to walking away from a $6.8 billion offer which values the gene research company’s shares at $51.…
Douglas A. McIntyre Biotech is a sector which is often mixed with a hodge-podge of winners and losers based on news flow from analysts and/or key drug developments which often have very little to do with…
Google (NASDAQ: GOOG) splits its stock in a way that will help its founders keep control, and the company also announces strong earnings. (Reuters) China’s GDP reaches a three-year low. (Reuters) Bank of…
Apartment vacancy rates reach a 10-year low, according to Reis. (Reuters) Tom Glocer, the departing head of Thomson Reuters (NYSE: TRI), makes $20 million. (Reuters) China’s premier, Wen Jiabao, says the monopoly…
Apple’s (NASDAQ: AAPL) iPad is the number one tablet PC in a new Consumer Reports survey. (Reuters) CEO pay jumps for last year as stock options rise. (Reuters) Avon (NYSE: AVP) turns…
The heads of the BRICÂ nations say the pace of IMF-led reforms concerns them. (Reuters) Facebook cuts trading of its stock in the secondary markets. (Reuters) The board of Goldman Sachs (NYSE: GS)…
Microsoft (NASDAQ: MSFT) struggles with its Windows Mobile OS as app developers have been slow to adopt it. (Reuters) Smugglers find it more difficult to make money on Apple (NASDAQ: AAPL) products…
The BP (NYSE: BP) oil trial is delayed for settlement talks. (Reuters) G20 ministers and central banks say Europe has to add money to its own funds before seeking outside aid. (Reuters)…
The Greeks try to get a financial aid package while some regional leaders say the eurozone does not need the southern European nation. (Reuters) A House committee pushes through plans for a…
Genetic biotech company Illumini (NASDAQ: ILMN) rejected an offer, now hostile, made by drug giant Roche. The Illimina board said that the “$44.50 per share cash offer is grossly inadequate in multiple respects.”…
Douglas A. McIntyre Illumina, Inc. (NASDAQ: ILMN) is the subject of a Roche takeover at $44.50 per share now, but many investors are expecting a much higher bid. The company has supposedly rebuffed all of…
Jon C. Ogg Illumina Inc. (NASDAQ: ILMN) had a solid day on Wednesday due to a hostile bid from Roche (RHHBY). The hope is that a higher bid may head Illumina’s way and the 52-week…
Jon C. Ogg 